Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person The prostaglandin F receptor (PTGFR) is a prostenoid recepto...

Class:IdSummation:9718112
_displayNameThe prostaglandin F receptor (PTGFR) is a prostenoid recepto...
_timestamp2021-03-16 15:54:51
created[InstanceEdit:9718121] Jassal, Bijay, 2021-03-16
literatureReference[LiteratureReference:9718113] Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension
[LiteratureReference:9718128] Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension
[LiteratureReference:9718051] Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models
modified[InstanceEdit:9718132] Jassal, Bijay, 2021-03-16
textThe prostaglandin F receptor (PTGFR) is a prostenoid receptor based on its ability, upon activation by prostaglandin F2α, to contract certain smooth muscle and smooth muscle-containing tissues such as those of the uterus and the eye. PTGFR is highly expressed in the uterine myometrium, the eye and the ovaries. PTGFR agonists (Abramovitz et al. 2000, Sharif et al. 2001, 2002, Neuschäfer-Rube et al. 2003) are primarily used to treat ocular hypertension and gluacoma, as well as eyelash hypotrichosis due to the autoimmune disease alopecia areata. The free acid forms of bimatoprost, latanoprost, tafluprost and travoprost (fluprostenol) are the active forms which are indicated for glaucoma and ocular hypertension. Latanoprostene bunod is a NO-donating analogue of the prostaglandin F2α agonist latanoprost (isopropyl ester) and benefits from the additive hypotensive actions of both the prostaglandin agonist and NO (determined in preclinical models, Kraus et al. 2011). Latanoprostene bunod is the first NO-donating prostaglandin analogue to be granted FDA marketing approval (Kaufman 2017, Fingeret et al. 2019).
(summation)[Reaction:9718020] PTGFR binds PTGFR agonists [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by The prostaglandin F receptor (PTGFR) is a prostenoid recepto... (9718112)
Follow Reactome